Telmisartan reduces progressive oxidative stress and phosphorylated α-synuclein accumulation in stroke-resistant spontaneously hypertensive rats after transient middle cerebral artery occlusion

J Stroke Cerebrovasc Dis. 2014 Jul;23(6):1554-63. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.051. Epub 2014 Apr 26.

Abstract

Telmisartan is an angiotensin receptor blocker with high lipid solubility, also called metabosartan, which exerts a special protective effect on both acute brain damage and chronic neurodegeneration. We examined the effects of telmisartan on oxidative stress by advanced glycation end product (AGE) and 4-hydroxynonenal (4-HNE) assays and the accumulation of phosphorylated α-synuclein (pSyn) in the brain of stroke-resistant spontaneously hypertensive rats (SHR-SR). At the age of 12 weeks, SHR-SR received transient middle cerebral artery occlusion (tMCAO) for 90 minutes and were divided into the following 3 groups: the vehicle group, the low-dose telmisartan group (.3 mg/kg/day), and the high-dose telmisartan group (3 mg/kg/day, postoperatively). Immunohistologic analysis was performed when rats were 6, 12, and 18 months old. AGE, 4-HNE, and pSyn-positive cells (per square millimeter) increased with age in the cerebral cortex and hippocampus of the vehicle group, in the low-dose telmisartan group, these parameters decreased without lowering blood pressure (BP), and in the high-dose telmisartan group, these parameters increased with lowering BP. The present study suggests that a persistent hypertension after tMCAO caused a progressive oxidative stress with the abnormal accumulation of pSyn, and that telmisartan reduced oxidative stress and the accumulation of pSyn without lowering BP (low dose) or improved these conditions with a reduction in BP (high dose) via its pleiotropic effects through a potential peroxisome proliferator-activated receptor gamma stimulation in the brain of SHR-SR.

Keywords: Parkinson's disease; Spontaneously hypertensive rat; oxidative stress; phosphorylated α-synuclein; telmisartan.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldehydes / metabolism
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Animals
  • Benzimidazoles / pharmacology
  • Benzimidazoles / therapeutic use*
  • Benzoates / pharmacology
  • Benzoates / therapeutic use*
  • Blood Pressure / drug effects
  • Brain / drug effects*
  • Brain / metabolism
  • Glycation End Products, Advanced / metabolism
  • Hypertension / metabolism
  • Infarction, Middle Cerebral Artery / drug therapy*
  • Infarction, Middle Cerebral Artery / metabolism
  • Male
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Oxidative Stress / drug effects*
  • Phosphorylation / drug effects
  • Rats
  • Rats, Inbred SHR
  • Rats, Wistar
  • Synucleins / metabolism*
  • Telmisartan

Substances

  • Aldehydes
  • Angiotensin II Type 1 Receptor Blockers
  • Benzimidazoles
  • Benzoates
  • Glycation End Products, Advanced
  • Neuroprotective Agents
  • Synucleins
  • 4-hydroxy-2-nonenal
  • Telmisartan